Erythema annulare centrifugum-like eruption associated with pegylated interferon treatment for hepatitis C


Submitted: 11 June 2013
Accepted: 8 July 2013
Published: 29 July 2013
Abstract Views: 3383
PDF: 628
HTML: 704
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Mark Naccarato Department of Infectious Diseases and HIV, St. Michael’s Hospital, Toronto, Ontario, Canada.
  • Deborah Yoong Department of Infectious Diseases and HIV, St. Michael’s Hospital, Toronto, Ontario, Canada.
  • Robert Solomon Department of Dermatology, St. Michael’s Hospital, Toronto, Ontario, Canada.
  • Mario Ostrowski Department of Infectious Diseases and HIV, St. Michael’s Hospital, Toronto, Ontario; Faculty of Medicine, University of Toronto, 1 King’s College Circle, Toronto, Ontario, Canada.
Current standard of treatment for chronic hepatitis C virus infection requires the use of pegylated interferon plus ribavirin. Treatment with these two agents has been associated with numerous side effects, which frequently include dermatologic eruptions. We report a cutaneous eruption associated with interferon having clinical presentation of erythema annulare centrifugum. The eruption occurred within days of the first interferon injection and repeatedly flared following subsequent injections. Our patient was able to continue therapy without interruption, while managing the reaction with topical corticosteroid and oral antihistamine. We conclude that this is a benign cutaneous eruption associated with interferon which can be managed without dis- continuing treatment for hepatitis C.

Supporting Agencies


Naccarato, M., Yoong, D., Solomon, R., & Ostrowski, M. (2013). Erythema annulare centrifugum-like eruption associated with pegylated interferon treatment for hepatitis C. Dermatology Reports, 5(1), e1. https://doi.org/10.4081/dr.2013.e1

Downloads

Download data is not yet available.

Citations